Latest Ratios: P/E Ratio -8.9x · EV/EBITDA N/A · ROE -32.3%. (1999–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $45M | $8M | $8M | $13M | $33M | $34M | $12M | $3M | $6M | — | — |
| Enterprise Value | $45M | $8M | $8M | $10M | $23M | $33M | $12M | $8M | $9M | — | — |
| P/E Ratio → | -8.87 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.84 | 0.51 | 0.56 | 1.33 | 3.77 | 5.60 | 3.73 | 1.16 | 3.23 | — | — |
| P/B Ratio | 3.15 | 0.67 | 0.58 | 0.77 | 1.35 | 2.41 | 0.88 | 0.54 | 0.43 | — | — |
| P/FCF | 210.15 | 37.59 | — | — | — | — | — | — | — | — | — |
| P/OCF | 103.40 | 18.49 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.50 | 0.53 | 1.11 | 2.61 | 5.41 | 3.90 | 2.81 | 5.06 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 36.96 | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 47.3% | 47.3% | 39.6% | 26.7% | 27.0% | 18.9% | 7.0% | 7.9% | 16.9% | -13.2% | -17.4% |
| Operating Margin | -26.4% | -26.4% | -50.1% | -136.0% | -108.6% | -150.1% | -351.6% | -485.8% | -900.2% | -502.2% | -556.3% |
| Net Profit Margin | -26.9% | -26.9% | -38.5% | -129.7% | -96.6% | -174.4% | -423.5% | -548.0% | -1201.0% | -489.1% | -1993.6% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -32.3% | -32.3% | -38.0% | -59.6% | -44.1% | -77.6% | -137.0% | -163.9% | -158.9% | — | — |
| ROA | -24.4% | -24.4% | -29.6% | -47.0% | -33.4% | -52.8% | -64.4% | -64.2% | -145.1% | -250.7% | -189.3% |
| ROIC | -24.3% | -24.3% | -40.3% | -66.9% | -52.7% | -51.4% | -67.1% | -77.2% | -512.8% | — | -207.4% |
| ROCE | -30.5% | -30.5% | -47.5% | -59.0% | -45.5% | -58.6% | -95.5% | -111.0% | -90.1% | — | -273.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | 0.08 | 0.09 | 0.06 | 0.11 | 0.10 | 0.83 | 0.27 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.01 | -0.03 | -0.13 | -0.42 | -0.08 | 0.04 | 0.77 | 0.24 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -0.63 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -56.97 | -56.97 | -423.33 | -1066.42 | -480.65 | -19.46 | -23.24 | -8.71 | -6.67 | -15.09 | -12.70 |
Net cash position: cash ($1M) exceeds total debt ($1M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.81 | 0.81 | 1.17 | 1.31 | 3.20 | 0.90 | 0.43 | 0.13 | 0.17 | 0.02 | 0.19 |
| Quick Ratio | 0.64 | 0.64 | 1.05 | 1.15 | 3.07 | 0.83 | 0.39 | 0.12 | 0.16 | 0.02 | 0.19 |
| Cash Ratio | 0.33 | 0.33 | 0.48 | 0.79 | 2.77 | 0.57 | 0.20 | 0.03 | 0.04 | 0.01 | 0.03 |
| Asset Turnover | — | 0.94 | 0.84 | 0.44 | 0.29 | 0.29 | 0.16 | 0.13 | 0.06 | 1.24 | 0.34 |
| Inventory Turnover | 11.61 | 11.61 | 23.90 | 9.75 | 11.45 | 14.12 | 15.80 | 13.40 | 8.89 | 73.42 | 38.80 |
| Days Sales Outstanding | — | 18.27 | 31.25 | 40.18 | 28.75 | 52.37 | 67.00 | 87.94 | 154.64 | 90.96 | 124.54 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 0.5% | 2.7% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $1M | $1M | $1M | $1M | $823853 | $284757 | $72055 | $15464 | $48 | $1369 |
Imminent liquidity and dilution
Based on reported figures, Precipio trades at a P/S ratio of 2.55, which appears to price the firm as a high-risk technology play rather than a stable diagnostic provider, reflecting significant market skepticism regarding the company's ability to achieve long-term profitability through its current decentralized testing model.
The negative P/E ratio and lack of meaningful EV/EBITDA metrics underscore that the market is currently valuing the company based on potential future adoption of its HemeScreen platform rather than current earnings. Investors should monitor whether this valuation premium can be sustained if revenue growth continues to stagnate, as the current multiple implies a growth trajectory that the recent 5.05% YoY revenue increase has yet to validate.
According to recent quarterly data, Precipio's ROIC has remained consistently negative, reaching -0.3% in 2025Q3, which suggests that the company is currently destroying shareholder value rather than compounding it through its specialized oncology diagnostic services and proprietary reagent product line.
The inability to generate positive returns on invested capital appears to be driven by the high fixed-cost burden of maintaining CLIA-certified facilities relative to the current revenue scale. This trend warrants further investigation into whether the company's pivot toward a product-heavy model can eventually improve capital efficiency or if the structural costs of the business will continue to suppress returns indefinitely.
As reported in financial statements, the company's cash conversion cycle has shown extreme volatility, with DSO reaching 116 days in 2025Q3, indicating that Precipio faces significant challenges in collecting payments from healthcare payers, which directly constrains its ability to fund operations through internal cash generation.
The extended DSO and DIO figures suggest that the company lacks the leverage to enforce favorable payment terms with its customers or manage inventory efficiently. This inefficiency forces a reliance on external financing to bridge the gap between service delivery and cash collection, creating a structural drag on the firm's liquidity position.
Based on the most recent quarterly filings, Precipio maintains a current ratio of 1.27, which, when combined with a cash balance of only $1.389 million, suggests a highly vulnerable liquidity position that leaves little room for error in managing its ongoing operating losses.
The company's reliance on equity-based financing to sustain operations is evident, as the low debt-to-equity ratio of 0.26 reflects limited access to traditional credit markets rather than a robust balance sheet. Investors should monitor the cash runway closely, as any delay in revenue recognition or unexpected spike in operating expenses may necessitate further dilutive capital raises.
Analysts frequently misapply the P/S ratio to Precipio, which obscures the underlying quality of the revenue stream and fails to account for the high cost of customer acquisition and the significant lag in cash collection inherent in the diagnostic services business model.
Using P/S as a primary valuation metric ignores the fact that a large portion of the company's revenue is tied to labor-intensive diagnostic services rather than high-margin, scalable product sales. A more appropriate approach would be to focus on the 'reagent pull-through' per installed platform, as this metric better captures the recurring revenue potential and the true economic value of the company's proprietary technology.
Includes 30+ ratios · 26 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PRPO stock.
Precipio, Inc.'s current P/E ratio is -8.9x. This places it at the 50th percentile of its historical range.
Precipio, Inc.'s return on equity (ROE) is -32.3%. The historical average is -65.6%.
Based on historical data, Precipio, Inc. is trading at a P/E of -8.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Precipio, Inc. has 47.3% gross margin and -26.4% operating margin.